Retatrutide vs Amycretin: Next-Gen Drug Showdown

Retatrutide and amycretin are both next-generation obesity drugs that go beyond single-receptor GLP-1 agonists. Retatrutide, developed by Eli Lilly, is a triple agonist targeting GLP-1, GIP, and glucagon receptors that achieved 24.2% weight loss in Phase 2 (Jastreboff et al., NEJM 2023). Amycretin, developed by Novo Nordisk, combines GLP-1 with amylin receptor agonism and showed striking early-phase results with up to 13.1% weight loss in just 12 weeks. These represent the two leading approaches to next-generation weight management.

Two Different Strategies to Beat Semaglutide

Both Eli Lilly and Novo Nordisk recognized that single-receptor GLP-1 agonists like semaglutide, while groundbreaking, have a ceiling. Their next-generation drugs add different second and third mechanisms to push past that ceiling — but they chose entirely different additional targets.

Retatrutide adds GIP and glucagon. The GIP receptor enhances insulin sensitivity and fat metabolism. The glucagon receptor increases energy expenditure and directly promotes liver fat oxidation. Together, these three receptors create a comprehensive metabolic reset.

Amycretin adds amylin to GLP-1. Amylin is a hormone co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon secretion after meals, and — critically — activates satiety centers in the brain through pathways distinct from GLP-1. The combination of GLP-1 and amylin produces additive appetite suppression through complementary central nervous system mechanisms.

Weight Loss Data Comparison

Why Amycretin's Early Data Is Exciting

Amycretin's 13.1% weight loss in just 12 weeks is one of the fastest rates of weight reduction ever recorded in obesity drug trials. If this pace were maintained — and that is a significant if — it could extrapolate to 25-30% or more over 48 weeks. This would potentially match or exceed retatrutide's results.

However, Phase 1 data must be interpreted with extreme caution. Small cohort sizes, shorter durations, and selection effects all tend to inflate early results. Nearly every obesity drug has shown rapid early weight loss that moderates as treatment continues and the body adapts. Whether amycretin can sustain its early pace is the critical unknown.

Unique Advantages of Each Drug

Retatrutide's Advantages

• Proven efficacy: 338-patient Phase 2 trial with 48-week data provides much more robust evidence
• Liver fat reduction: Glucagon receptor provides direct hepatic fat oxidation that amycretin lacks
• Energy expenditure: Only retatrutide actively increases metabolic rate through glucagon
• Further in development: Phase 3 TRIUMPH trials underway, closer to potential approval

Amycretin's Advantages

• Speed of weight loss: Early data suggests faster initial weight reduction
• Oral formulation: Novo Nordisk is developing both injectable and oral versions
• Additive satiety: Amylin + GLP-1 may produce stronger appetite suppression than any other combination
• Novo Nordisk expertise: Leverages the same company that developed semaglutide

Side Effect Considerations

Both drugs share GI side effects from GLP-1 receptor activation. Retatrutide adds glucagon-specific effects including mild heart rate increase (2-4 bpm), potential liver enzyme elevations, and dysesthesia (skin tingling). These are generally transient and manageable.

Amycretin's amylin component can cause nausea and reduced appetite — which overlaps significantly with GLP-1 effects. The combined appetite suppression may be more intense, potentially leading to very low caloric intake that requires careful monitoring. Full safety data from larger trials is needed for both drugs.

Timeline to Market

Retatrutide is further along in development with Phase 3 TRIUMPH trials actively enrolling. Estimated FDA approval: late 2027 to 2028. Amycretin is still in earlier clinical development, with Phase 2 trials ongoing. Estimated FDA approval: 2028 to 2029 at the earliest. Both timelines are approximate and subject to clinical trial outcomes.

Available Treatment Today

Neither retatrutide nor amycretin is available today. If you are ready to start weight loss treatment now, proven GLP-1 medications are accessible and affordable. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month — medications that produce 15-22% average weight loss. You can always transition to next-generation drugs when they become available. Get started with Trimi today.

Frequently Asked Questions

Is amycretin better than retatrutide?

It is too early to say. Amycretin has only Phase 1 data while retatrutide has robust Phase 2 results. Amycretin's early rate of weight loss is impressive, but whether it can sustain that pace in larger, longer trials remains unknown.

Will amycretin replace semaglutide?

Novo Nordisk positions amycretin as a next-generation successor to semaglutide, similar to how tirzepatide advanced beyond liraglutide. If Phase 2/3 data confirms early results, amycretin could become Novo Nordisk's flagship obesity drug.

Can you take amycretin as a pill?

Novo Nordisk is developing both oral and injectable formulations of amycretin. An effective oral formulation producing 20%+ weight loss would be a major advance in the field, though oral versions typically show somewhat lower efficacy than injectable.

Which next-gen drug should I wait for?

We recommend not waiting. Start treatment with available medications now and transition to next-gen options as they become available. Every month of untreated obesity increases health risks.